Santos Castañeda
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Rehberg M, Choy E, Rubbert-Roth A, Castañeda S, Schwarting A, Gottenberg J, Curtis J, Iglesias-Rodriguez M, van Hoogstraten H, Praestgaard A, Giegerich C, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther 2021; 8:1921-1922.
01.12.2021Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
01.12.2021Rheumatol Ther 2021; 8:1921-1922
Rehberg Markus, Choy Ernest H S, Rubbert-Roth Andrea, Castañeda Santos, Schwarting Andreas, Gottenberg Jacques-Eric, Curtis Jeffrey R, Iglesias-Rodriguez Melitza, van Hoogstraten Hubert, Praestgaard Amy, Giegerich Clemens, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Rehberg M, Choy E, Rubbert-Roth A, Castañeda S, Schwarting A, Gottenberg J, Curtis J, Iglesias-Rodriguez M, van Hoogstraten H, Praestgaard A, Giegerich C, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther 2021; 8:1661-1675.
14.09.2021Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
14.09.2021Rheumatol Ther 2021; 8:1661-1675
Rehberg Markus, Choy Ernest H S, Rubbert-Roth Andrea, Castañeda Santos, Schwarting Andreas, Gottenberg Jacques-Eric, Curtis Jeffrey R, Iglesias-Rodriguez Melitza, van Hoogstraten Hubert, Praestgaard Amy, Giegerich Clemens, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators
A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility
González-Serna D, Boiardi L, Emmi G, Cimmino M, Vaglio A, Herrick A, Denton C, Salvarani C, Cid M, Morgan A, Fonseca C, González-Gay M, Martín J, Beretta L, Holle J, Neumann T, Carmona E, Ortego-Centeno N, Simeón C, Solans R, Hernández-Rodríguez J, Tolosa C, Castañeda S, Narváez J, Martinez-Valle F, European GCA Consortium, European Scleroderma Group, Witte T, Márquez A. A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PloS one 2018; 13:e0209343.
26.12.2018A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility
26.12.2018PloS one 2018; 13:e0209343
González-Serna David, Boiardi Luigi, Emmi Giacomo, Cimmino Marco A, Vaglio Augusto, Herrick Ariane L, Denton Christopher P, Salvarani Carlo, Cid María C, Morgan Ann W, Fonseca Carmen, González-Gay Miguel A, Martín Javier, Beretta Lorenzo, Holle Julia, Neumann Thomas, Carmona Elio G, Ortego-Centeno Norberto, Simeón Carmen P, Solans Roser, Hernández-Rodríguez José, Tolosa Carlos, Castañeda Santos, Narváez Javier, Martinez-Valle Ferran, European GCA Consortium, European Scleroderma Group, Witte Torsten, Márquez Ana